Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

mal responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the 18 responding patients (44%), 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with R
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
(Date:9/19/2014)...  CytRx Corporation (Nasdaq: CYTR ), a ... announced that David J. Haen , Vice President, ... the Biotech Industry Conference on Friday, September 26 th ... place at the Millennium Broadway Hotel in ... and archived webcast of the presentation will be available ...
(Date:9/19/2014)... VIENNA, Austria , September 19, 2014 ... glucose control persist for many years in people with ... to produce major long term benefits for the kidneys." ... control in patients with type 2 diabetes leads to ... to usual care. The global study has ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Hope for Treatment of,Children, WHITE PLAINS, N.Y., Feb. ... rare craniofacial birth defect in,mice and holds promise to ... funded in part by the March of Dimes., ... Nature Medicine,demonstrates the potential for translating basic research into ...
... BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. ... "Company"), a,pharmaceutical company in the People,s Republic ... achieved significant milestones in the development of,isosorbide ... drug,for the prevention and treatment of angina., ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:9/21/2014)... the physical activity benefits of active play, a new ... children, playing has no goal it is an ... alone or with friends, and it represents "an opportunity ... boredom, sadness, fear, or loneliness." "By focusing on the ... aspects of play that are beneficial to young people,s ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 2014 Over the past five years, ... inundate the market, thereby cutting into revenue growth for ... to data from Industry Canada, the loss of patent ... and $2.5 billion in 2010 and 2012, respectively. “In ... which has hampered revenue growth, many pharmaceutical manufacturers have ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Oct. 8 Boston Scientific,(NYSE: BSX ) announced ... third quarter results, which it plans to report on ... a $250 million milestone,payment from Abbott Laboratories (NYSE: ... Guidant,s vascular intervention and endovascular,solutions businesses. As a result, ...
... Weight Watchers,International, Inc. (NYSE: WTW ) ... serve as its President, North America, effective November,3, ... product,operations and general management experience, will oversee the ... products,publishing and licensing businesses and will be reporting ...
... sometimes goes awry has been implicated in breast cancer. ... of the Notch pathway may contribute to breast cancer. ... Drs Jane Visvader and Geoff Lindeman from the Victorian ... Notch genes in regulating breast development and function. ...
... Bulletin Board:,VYTC) today announced that effective October 7, ... an independent scientific consultant to Vyta Corp.,Dr. Sorgente ... at,BIOAGRA, LLC, a joint venture, equally owned by ... 2008, Vyta Corp announced its filing of,foreclosure litigation ...
... 8 Mass casualty incidents --,such as terrorist ... or hurricanes -- raise the life-and-death reality that,existing ... for all who,need it. One of the most ... requiring respiratory support., Disaster specialists and health ...
... Tampa, FL (Oct. 8, 2008) Women, the elderly, ... are all less likely to receive same-day coronary angioplasty ... South Florida researchers found. Their study was published this ... Cardiology . , Angioplasty, also known as percutaneous ...
Cached Medicine News:Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 2Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: